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Dear Home Secretary and Secretary of State for Health, 
  
Re: ACMD advice on tramadol  
 
I am writing to provide you both with advice from the Advisory Council on the 
Misuse of Drugs (ACMD) on the compound tramadol ((±)-trans-2-
((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol). The 
recommendations concern both the Home Office (recommendations 1 and 2) and 
the Department of Health (recommendation 3).     
 
The ACMD‟s review of harms associated with the non-medicinal use of tramadol 
was prompted by an increasing number of reports within the NHS of tramadol‟s 
misuse and harms. The ACMD‟s subsequent review of the evidence has caused 
it concern, particularly the increase in tramadol related deaths.  
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Tramadol’s pharmacology, misuse and harms 
 
Tramadol is a synthetic analogue of the phenanthrene alkaloid codeine and is an 
analgesic of significant medical use for treating moderate to severe pain. 
Tramadol has wide ranging applications, including the treatment of fibromyalgia 
(chronic widespread pain), cancer pain and moderate to severe musculoskeletal 
pain. In a similar way to other psychoactive agents of the opioid class, it can be 
liable to misuse. 
 
Tramadol has a unique dual-action pharmacological profile that increases the risk 
of adverse effects seen in overdose. Opioids such as tramadol exhibit weak 
agonist activity at opiate receptors in the brain and may contribute towards 
euphoria and respiratory depression. In addition, tramadol enhances 
serotoninergic and noradrenergic systems in the brain by inhibiting their reuptake 
mechanisms. 
 
Prescribing data from the NHS Business Services Authority (NHSBSA) indicate 
an increase in prescribing, with the number of Daily Defined Doses (England)1  
increasing from approximately 5.9 million in September 2005 to 11.1 million in 
September 2012. This may be associated with Co-Proxamol‟s phased withdrawal 
from 2005.   
 
Data from the Office of National Statistics (ONS) for 2011 shows 154 deaths 
where tramadol had been mentioned on the death certificates; in 2009 there 
were 87 such mentions and in 2008 this figure was 83. The majority of tramadol 
related deaths are where it has been obtained through non–prescribed means.  
 
 
ACMD advice 
 
The ACMD advises that tramadol be controlled as a class C substance under the 
Misuse of Drugs Act 1971 and listed in Schedule III of the Misuse of Drugs 
Regulations 2001, which it considers would provide the correct controls to 
prevent diversion and misuse. 
 
  
                                                 
1
 The Defined Daily Doses (DDD) is a measure of prescribing volume maintained by the World 
Health Organisation (WHO) based upon international prescribing behaviour. It represents the 
assumed average maintenance dose per day for a drug used for its main indication in adults. The 
DDD is not a recommended dose but an analytical unit to compare prescribing activity. 
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The ACMD also advises that prescribers and other healthcare professionals who 
come into contact with people using tramadol should be given appropriate 
training and support concerning its misuse and adverse effects, especially with 
regards to its „dual-action‟.  
 
 
Yours sincerely,  
 
 
 
Professor Les Iversen FRS CBE 
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1. Background and scope 
1.1. The ACMD is established under the Misuse of Drugs Act 1971 (hereafter 
termed the „Act‟) and its purpose is to keep under review the drugs situation 
in the UK and provide advice to ministers. That advice may be concerned 
with; restricting availability, facilities and treatment (recovery), promoting co-
operation between professional and community services, educating the 
public and promoting research. 
 
1.2. This review follows concerns reported to the ACMD by an NHS Primary Care 
Trust (PCT) surrounding the non-medicinal use of tramadol. This includes 
tramadol that is illicitly obtained or prescribed legitimately but then misused. 
The PCT led a Controlled Drugs Local Intelligence Network, through which it 
had received an increasing number of reports of tramadol‟s misuse and 
harms. 
 
1.3. This report examines the pharmacology of tramadol, its current non-
medicinal use in the UK and the harms associated with tramadol use 
(medicinally and non-medicinally). 
 
2. Introduction 
2.1. Tramadol is a synthetic opioid with effects similar to those of codeine. It is an 
analgesic of significant medical use and has wide ranging applications mostly 
in the treatment of moderate to severe pain and including the treatment of 
fibromyalgia (wide spread chronic pain), cancer pain and moderate to severe 
musculoskeletal pain.   
2.2. Tramadol is classified as an “other opioid” under the World Health 
Organisation (WHO) Anatomical Therapeutic Chemical (ATC) classification 
system and sits on step two of the WHO analgesic ladder with opiates such 
as codeine and dihydrocodeine. It is regarded as equipotent to these two 
opiates. 
2.3. Tramadol has other trade names such as Zydol®, Zamadol® and Marol®.  
2.4. The ACMD understands that tramadol is widely available on-line and easily 
obtainable without prescription. Current medicines legislation does not 
prohibit the importation of a medicine, provided it is for personal use and not 
for onward supply.  
2.5. The side effects of tramadol can include hallucinations, agitation, fever, 
overactive reflexes, nausea, vomiting, loss of coordination, fainting and 
elevated heart rate.   
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2.6. Figures for England indicate that Defined Daily Doses (DDD) 2 have 
increased from approximately 5.9 million in September 2005 to 11.1 million in 
September 2012 (Figure 1). 
2.7. Compared to other analogous compounds e.g. dihydrocodeine it would 
appear an anomaly that tramadol is an opioid outside the Misuse of Drugs 
Act 1971. The ACMD notes the level of licit prescribing of tramadol as 
suggested by recent data (Figure 1). 
2.8. The Medicines and Healthcare products Regulatory Agency (MHRA) has 
received 67 referrals regarding or linked to tramadol (some referrals have 
included other medicines as well). As a result, the MHRA has launched a 
number of investigations, some of which were linked to the counterfeiting of 
tramadol.  
 
 
Figure 1. National DDD usage for tramadol (September 2005 to September 
2012). 
 
  
                                                 
2
 The Defined Daily Doses (DDD) is a measure of prescribing volume maintained by the World 
Health Organisation (WHO) based upon international prescribing behaviour. It represents the 
assumed average maintenance dose per day for a drug used for its main indication in adults. The 
DDD is not a recommended dose but an analytical unit to compare prescribing activity 
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International Perspective  
2.9. The legal status of tramadol differs internationally, from being available over 
the counter in Kuwait and Thailand to being a controlled (Schedule 4) 
prescription drug in Australia since 2001. In Sweden it has been controlled in 
the same manner as dextropropoxyphene and codeine since 2008, and in 
Norway, Ireland and Germany it is a prescription only medicine. The ACMD 
understands that in the USA tramadol is controlled under some states‟ laws 
(Schedule 4) e.g., Arkansas and Kentucky.  
 
3. Pharmacology and Toxicology 
Pharmacology 
3.1. Tramadol – (±)-trans-2-((dimethylamino)methyl)-1-(3-
methoxyphenyl)cyclohexanol – is a synthetic opioid with effects similar to 
those of codeine. It is an analgesic with weak agonist activity at µ-opioid 
receptors in the brain (Ki = 2400 nM; Gillen et al., 2000). The affinity of 
tramadol for the µ-opioid receptor is only 1/6000 of that of morphine although 
its selectivity for this sub-type of receptor is greater than that of morphine. Its 
analgesic activity is also probably contributed to by monoaminergic activity 
resulting from inhibition of re-uptake of both noradrenaline and serotonin and 
from some agonist activity at α2_adrenergic receptors. The fact that, in 
contrast to other opioids, the analgesic action of tramadol is only partially 
inhibited by the opioid antagonist naloxone lends support to the view that 
these other actions play a role in its analgesic activity. However, Duke et al. 
(2011) found that subjects trained to discriminate the subjective effects of an 
opiate (dihydromorphine) from those caused by a stimulant 
(methylphenidate) recognised tramadol as an opiate drug. Gillen et al. (2000) 
reported that the primary O-desmethylated metabolite of tramadol interacts 
potently with the cloned human µ-opioid receptor (Ki = 3.4 nM), making it 
more than 700 times more potent than the parent compound. This suggests 
that the O-demethylated metabolite may account for most of tramadol‟s 
opiate-mediated analgesic activity (Gillen et al., 2000)3. A range of other 
pharmacological actions have been attributed to tramadol. In particular, it has 
been reported as having actions on various G-protein coupled receptors 
(GPCRs) and on ion channels. There are specific reports of actions as an 
NMDA receptor antagonist, a 5-HT2c receptor antagonist, and an antagonist 
at both nicotinic and muscarinic acetylcholine receptors (Minami et al., 2007). 
The significance of these actions in the therapeutic use of the drug or in the 
development of adverse reactions is not clear. 
                                                 
3
 The ACMD provided advice on the misuse and harms of O-desmethyltramadol in 2012. The legislative 
process for control of the substance under the Misuse of Drugs Act 1971 is underway. 
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3.2. Tramadol is a racemic mixture4, the parent racemate being more potent as 
an analgesic than either of its enantiomers although the (+) enantiomer does 
bind to the µ-opioid receptor and does inhibit the re-uptake of serotonin. The 
(-) enantiomer inhibits the re-uptake of noradrenaline and stimulates 
α2_receptors (Raffa, 2008).  
3.3. Tramadol undergoes liver metabolism and is excreted via the kidney. The 
elimination half-life is 6 hours for tramadol and 7.5 hours for its active 
metabolite. The analgesic effect begins within about an hour of oral dosing, 
peaks at 2-3 hours and lasts for about 6 hours. The maximum recommended 
daily dose by mouth is 400mg (Dayer, et al., 1997). 
3.4. Tramadol is about as effective as morphine in the relief of mild to moderate 
pain but less effective in the treatment of severe or chronic pain. Reported 
subjective effects in therapeutic use include euphoria and other reported 
effects include dizziness, headache, agitation, nausea, vomiting and 
seizures. It appears to cause less respiratory depression that other opioids, 
but this is still a risk with large doses of tramadol, either therapeutically or in 
overdose. Patients with renal impairment and extensive CYP2D6 
metabolisers are at enhanced risk of toxicity (Stamer, et al., 2008). 
3.5. In summary, although tramadol has a complex pharmacology, its analgesic 
action results mainly from its agonist effects at opioid receptors with an 
additional contribution from the monoaminergic activity due to its inhibition of 
the re-uptake of serotonin and noradrenaline. This dual mechanism 
increases the potential for adverse effects, particularly in overdose, and has 
led to debates about whether or not tramadol should be classified as an 
opioid and whether its toxicity, including misuse and dependency potential, 
should be regarded as being different from that of other opioids (Raffa, 2008; 
Epstein, et al., 2006). 
      Toxicology 
3.6. Tramadol overdose results in drowsiness, constricted (small) pupils, 
agitation, tachycardia (rapid heartbeat), hypertension (high blood pressure), 
and nausea, vomiting and sweating. Seizures are more common with 
tramadol overdose than with other opioids and occur in up to 15% of cases. 
In severe poisoning coma, seizures and hypotension (low blood pressure) 
can occur; respiratory depression is less common than with other opioids 
unless the individual has taken other central nervous system depressants. 
                                                 
4
 A racemic mixture is one that comprises of left- and right-handed enantiomers (i.e. mirror 
images) in equal amounts. 
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3.7. Due to the fact that tramadol inhibits serotonin re-uptake, tramadol overdose 
can cause serotonin syndrome. This can be potentially fatal with severe 
serotonin syndrome being characterised by hyperpyrexia (very high body 
temperature) associated with secondary complications including 
rhabdomyolysis (breakdown of skeleton muscle), disseminated intravascular 
coagulation (formation of blood clots) and acute kidney injury. This syndrome 
is more likely to occur with co-administration of another drug that increases 
serotonin activity such as certain antidepressants (e.g. monoamine oxidase 
inhibitors, SSRIs (Selective serotonin re-uptake inhibitors)) and stimulant 
recreational drugs with serotonergic activity (e.g. MDMA (ecstasy), 
amphetamines, cathinones (e.g. mephedrone)). 
3.8. The fact that only the opioid effects of tramadol are reversible with naloxone 
makes this drug more likely to cause harm than other opioids especially 
when combined with other monoamine-active drugs as noted above. 
 
4. Dependence liability and misuse 
4.1. One view is that „tramadol has pharmacodynamic and pharmacokinetic 
properties that are highly unlikely to lead to dependence‟ (Dayer, et al., 1997) 
and in another paper it is stated that „while abuse of tramadol may occur, 
several large studies have demonstrated that the incidence of abuse is rather 
low, about one case per 100,000 patients‟ (Reeves and Burke, 2008).  
However, some authors have suggested incidence of abuse or dependence 
as high as 6.9/1000 in some cohorts of users (Knisely, et al., 2002). 
4.2. Tramadol has been reported as having a lower potential for dependence 
compared to morphine and animal studies have demonstrated a lower abuse 
potential than codeine and pentazocine (Epstein, et al., 2006).  The 
Summary of Product Characteristics for Zydol® capsules, which contain the 
active ingredient tramadol hydrochloride, also highlight that they have a “low 
dependence potential” (Martindale, The Extra Pharmacopoeia, 2009). In 
2006 a WHO expert committee on drug dependence reviewed tramadol and 
concluded that, despite an increase in its use, it continued to show a low 
level of misuse and that there was not sufficient evidence to justify a further 
review (WHO, 2006).   
4.3. Reports of dependence and misuse in the UK through the National Drug 
Treatment Monitoring System (NDTMS) highlighted just over 300 cases 
since 2004 of tramadol being reported as a primary drug in England with 200 
cases reporting tramadol as a secondary drug.  Although it is difficult to give 
an accurate figure of how many individuals this relates to (multiple episodes 
can be recorded for one individual presenting to treatment) it has been 
estimated that it relates to about 200 individuals (Donmall, 2010). 
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4.4.  Where physical dependence to tramadol develops the withdrawal syndrome 
(Barsotti, et al., 2003) can be severe with symptoms typical of opiate 
withdrawal sometimes accompanied by atypical symptoms including 
seizures. The latter are probably related to the effects of monoamines.  
4.5. It is relevant to note that the somewhat more potent but related drug 
tapentadol which has recently been licensed for clinical use is a Schedule II 
drug. A research report by Terault, et al. (2007) examined gender and non-
medicinal use of a number of prescription opioids in the USA (Table 1). 
 
Table 1.  Lifetime non-medicinal use of individual opioids among the total 
sample, and among those with past-year non-medicinal use of prescription 
opioids, stratified by gender. 
4.6. Table 1 shows that of the total sample of 55023 individuals, 373 or 0.5% had 
reported lifetime non-medicinal use of tramadol.  Past year use demonstrates 
high prevalence rates for the stronger opioids also with Vicodin® 
(hydrocodone and paracetamol) and Perocet® (oxycodone and paracetamol) 
at 65.4% and 38.5% respectively, compared to 5.6% for Tramadol. 
4.7. The website EROWID (online user forum) provides 221 user reports 
associated with the non-medicinal use of tramadol5.  The reports support the 
assumption that tramadol is used as a non-medicinal agent by users for its 
psychoactive qualities with a variety of „positive‟ and „negative‟ effects 
reported by users. 
4.8. The 2011 Street Drug Trends survey has also indicated that there has been 
a rise in tramadol use in the last year in 16 of the 20 areas investigated in the 
UK (Daley and Simonson, 2011). 
                                                 
5
 Accessed on 7
th
 December 2012 
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4.9. The ACMD is not aware of academic literature that investigates the 
breakdown of how individuals‟ access tramadol supplies, although tramadol 
remains widely available on prescription. Tramadol is widely available on the 
internet without prescription. The ACMD considers that the diversion of licit or 
prescription supplies would be a route that some individuals use and is 
aware of some case study reports from the South West of England that 
support this. 
4.10. The ACMD is not aware of academic literature in the UK that has 
investigated the societal harms associated with tramadol misuse.  Tramadol 
has been implicated as a drug that has “fuelled a lucrative criminal economy 
of illicit drugs” in the Occupied Palestinian Territories (Gaza) with its 
associated loss of tangibles for the individuals involved (there were 591 
tramadol related arrests in 2009 in Occupied Palestinian Territories (Gaza) 
(Progler, 2010). However, it would be difficult to generalise these to the UK 
considering the difference between the two territories. The ACMD is  mindful 
that tramadol dependence has been reported in the UK from data provided 
by the National Drug Treatment Monitoring System (NDTMS) database (see 
paragraph 4.3) and understand the impact opioid dependence can have on 
users and affected others. 
4.11. The Medicines, Healthcare Products Regulatory Agency (MHRA) monitors 
adverse effects through the yellow card system.  Information from their drug 
analysis print for tramadol from January 1983 (first recorded adverse effects 
to the MHRA) to 5th January 2011 shows : 
        6073 „reactions‟ to tramadol with 60 fatalities; 
        the most common system organ class for an adverse reaction was 
„nervous system disorders‟ (22.4%) with „dizziness‟ the most 
common individual reaction in this group; 
        the top three categories for fatalities adverse reaction were, injuries 
(22%), general disorders (20%) and respiratory disorders (18%);  
        under substance-related disorders the following number of adverse 
effects have been reported: 
 
Alcohol withdrawal syndrome: 1  Drug dependence: 22 
Dependence: 27     Nicotine dependence: 1 
Drug abuse: 5     Withdrawal syndrome:168 
 
4.12. The accuracy of this data depends on accurate reporting and recognition of 
symptoms from the reporter. Numbers above could be higher as many 
adverse effects may go unreported through the yellow card system. 
Nevertheless, through the MHRA, dependence and withdrawal symptoms 
have been reported as being associated with tramadol. 
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5. Deaths attributed to tramadol 
5.1. Two reports on the number of deaths where selected substances were 
mentioned on death certificates in England and Wales also highlights the role 
of tramadol in drug related deaths.   
5.2. Tramadol has been mentioned in a number of deaths reported to the 
National Programme of Substance Abuse Deaths (np-SAD).  Table 2 
highlights an increasing trend since 1998 when only two mentions of 
tramadol were noted, with 123 mentions in 2009.  
 
Table 2: Number of: a) “mentions” of tramadol in deaths b) deaths where 
tramadol has been implicated c) % of deaths where tramadol was the sole agent 
and d) % of deaths where tramadol was not prescribed or the route of supply was 
“not known” reported to the np-SAD by the end of June 2012.  
 
Year Number of 
mentions of 
tramadol 
Deaths where 
tramadol was 
implicated 
% of implicated 
deaths where 
tramadol was the 
“sole agent” 
(number) 
% of implicated 
deaths where 
tramadol was NOT 
prescribed or “not 
known”(number) 
1998 2 2 50 (1) 0 (0) 
1999 9 12 8 (1) 33 (4) 
2000 9 10 30 (3) 70 (7) 
2001 29 33 15 (5) 58 (19) 
2002 19 19 21 (4) 53 (10) 
2003 38 37 22 (8) 41 (15) 
2004 55 45 36 (16) 67 (30) 
2005 61 53 34 (18) 62 (33) 
2006 85 76 25 (19) 68 (52) 
2007 96 82 17 (14) 62 (51) 
2008 97 80 21 (17) 61 (49) 
2009 138 111 11 (12) 64 (59) 
2010 133 109 21 (23) 63 (58) 
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5.3. The information provided by np-SAD also shows: 
       a prominent diversion problem with up to 64% of deaths (2009) where 
tramadol has been implicated coming from non-prescribed routes or 
where the source was unknown; and, 
 
       a trend towards poly-drug use with only 17% of tramadol implicated 
deaths in 2007 involving tramadol as the sole agent.  
 
Drug 2006 2007 2008 2009 2010 2011 
Total mentions: All 
deaths from drug-
related poisoning: 
Methadone 
 
All benzodiazepines 
 
All anti-depressants 
 
Paracetamol (including 
combination products)6 
 
Codeine 
 
Dihydrocodeine 
 
Tramadol 
  
  
 
 
241 
 
177 
 
336 
 
309 
 
 
60 
 
96 
 
81 
  
  
 
 
325 
 
207 
 
335 
 
242 
 
 
60 
 
85 
 
79 
 
 
 
 
378 
 
230 
 
381 
 
260 
 
 
70 
 
79 
 
83 
 
 
 
 
408 
 
261 
 
405 
 
255 
 
 
90 
 
99 
 
87 
 
 
 
 
355 
 
307 
 
381 
 
199 
 
 
91 
 
90 
 
132 
 
 
 
 
486 
 
293 
 
393 
 
207 
 
 
*7 
 
* 
 
154 
 
Table 3:Number of deaths where selected substances were mentioned on 
death certificates. Deaths related to drug poisoning in England and Wales 
2006-10 (ONS). 
 
5.4. According to data from the ONS, the number of deaths involving tramadol 
have also been steadily increasing since 1993 (when ONS records began), 
with deaths showing a marked rise from 87 in 2009 to 154 in 2011 (an 
increase of 77 per cent) (Table 3).  
                                                 
6
 Dextropropoxyphene is very rarely ingested except in combination with paracetamol, therefore 
figures include dextropropoxyphene mentioned without paracetamol. 
7
 Notes (ONS) Specific rules were adopted for dealing with compound analgesics which contain 
relatively small quantities of drugs listed under the Misuse of Drugs Act, the major ones being 
dextropropoxyphene, dihydrocodeine and codeine. Where these drugs are mentioned on 
a death record, they have been excluded from the drug misuse indicator if they are part of 
a compound analgesic (such as co-proxamol, co-dydramol or co-codamol) or cold remedy. 
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5.5. Table 3 shows that deaths where tramadol was mentioned on the death 
certificate have increased (apart from a small decrease in 2007). It is 
important to note this increase has occurred at a time when there has been a 
large increase in prescribing. Table 3 also highlights the role of other drugs in 
drug-related poisonings. 
5.6. The 2009 Drug-related deaths in the UK report published by the np-SAD 
mentions that the proportion of deaths involving tramadol rose from 2.2% in 
2004 to 3.6% in 2006 and has since remained stable (Ghodse, et al., 2009). 
5.7. A review of deaths related to analgesic and cough suppressant-opioids in 
England and Wales between 1996 and 2002 by Schifano et al. in 2006 
illustrated that codeine and dihydrocodeine were reported in about 28% of 
cases with a smaller number related to other analgesics (including tramadol) 
(Office National Statistics, 2008). 
5.8. When interpreting these figures it should be noted that the prescribing of 
tramadol has also increased since the phased withdrawal of Co-Proxamol 
between January 2005 and December 2007. Figures for England indicate 
that DDD have increased from approximately 5.9 million in September 2005 
to 11.1 million in September 2012 (Figure 1). 
5.9. The phased withdrawal of co-proxamol in 2005 may have impacted on 
tramadol prescribing levels as prescribers sought alternative analgesia (see 
Figure 2). However, it should be noted that the number of prescriptions for 
opioid analgesics dispensed in England have also increased significantly 
over the same period (Figure 1). A report from the National Treatment 
Agency (NTA) in 2011 illustrates that from 1991 to 2009 opioid analgesic 
medication dispensed in England has increased by over fivefold (NTA, 2011) 
(Figure 2). Therefore, it is not clear whether this is a general trend or whether 
the phased withdrawal has had a significant impact on prescribing levels. 
Nevertheless, it is clear that levels of prescribing have increased as have 
drug related deaths where tramadol has been mentioned. 
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Figure 2: trends in prescribing of opioid analgesics hypnotics and anxiolytics 
(by number of prescriptions (millions) and quantity in the number of items 
dispensed (1991-2009) (NTA, 2011). 
 
6. Conclusions and Recommendations 
6.1. Tramadol is a widely prescribed analgesic of significant medical use for the 
treatment of moderate to severe pain. In a similar way to other psychoactive 
agents of the opioid class, it is liable to misuse.  
6.2. Tramadol‟s unique dual-action pharmacological profile increases the risk of 
adverse effects, particularly in overdose. The symptoms of tramadol 
overdose include rapid heart beat, high blood pressure, vomiting and 
seizures. Tramadol overdose can cause serotonin syndrome, which is 
potentially fatal. Treatment of tramadol overdose with naloxone only reverses 
the opioid effects, therefore, it is more likely to cause harm than other 
opioids, especially when combined with other monoamine-active drugs e.g., 
ecstasy.  
6.3. The NDTMS highlighted just over 300 cases since 2004 of tramadol being 
reported as a primary drug of use in England, with 200 cases reporting 
tramadol as a secondary drug. It has been estimated that it relates to about 
200 individuals. The 2011 Street Drug Trends survey has also indicated that 
there has been a rise in tramadol use in the last year in 16 of the 20 areas 
investigated in the UK.  
6.4. Data from the ONS for 2011 shows 154 deaths where tramadol had been 
mentioned on the death certificates; in 2009 there were 87 such mentions 
and in 2008 this figure was 83. The majority of tramadol related deaths are 
where it has been obtained through non–prescribed means.    
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6.5. The ACMD is not aware of academic literature that investigates the 
breakdown of how individuals‟ access tramadol supplies, although tramadol 
remains widely available on prescription and on the internet without 
prescription. The ACMD considers that the diversion of licit or prescription 
supplies would be a route that some individuals use. 
6.6.  The ACMD are not aware of academic literature in the UK that has 
investigated the societal harms associated with tramadol misuse. However, 
tramadol dependence has been reported in the UK from data provided by the 
NDTMS and it is important to recognise the impact opioid dependence can 
have on users and society.   
Recommendation 1 
The ACMD considers the harms associated with tramadol are 
commensurate with other Class C drugs and recommends that it is 
controlled under the Misuse of Drugs Act 1971 as a Class C substance. 
 
6.7. The ACMD is aware that tramadol is widely available on the internet without 
prescription. There is some evidence to suggest diversion of prescription 
supplies destined for misuse, however, the ACMD does not have evidence to 
quantify this (see paragraph 4.10). 
6.8. The ACMD considers that to provide an appropriate level of control, both due 
to the complex pharmacology of tramadol making this drug more likely to 
cause harm than other equipotent opioids and to enable additional 
monitoring particularly around private prescribing,  the most appropriate 
Schedule for tramadol would be Schedule III.  
6.9. It is important to note that in the absence of evidence from clinical practice, 
the ACMD is unclear whether the prescription requirements associated with 
Schedule III could present further burden for prescribers. Should the Home 
Office consider implementing the above recommendation, the ACMD would 
consider it prudent for it to consult with health and social care practitioners on 
the impact of Schedule III (Regulation 15) requirements to ensure any 
change is proportionate to the harms and risk of diversion outlined by the 
ACMD in this report. 
Recommendation 2 
Tramadol be scheduled as a Schedule III drug under the Misuse of 
Drugs Regulations 2001 (as amended). 
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6.10. The DDD for tramadol of 11.1 million (September 2012, up from 5.9 million in 
September 2005), reflects the level of prescribing by practitioners. As with all 
medicines that are scheduled under the Misuse of Drugs Regulations, 
irrespective of scheduling category it is required that prescribers are provided 
with adequate training and information to ensure the safe use of the medicine 
given. The judicious prescribing of tramadol is essential to its safe use.  
6.11. Given the widespread prescribing of tramadol it is important that there is 
appropriate information and training provided to prescribers. The raising of 
awareness among prescribers of the potential harms associated with the 
misuse of tramadol would assist in addressing issues such as the improper 
prescribing of tramadol (as highlighted by the North of Tyne Intelligence 
Network) and the risks of diversion. 
6.12. The misuse of tramadol, from whatever source, presents potential physical 
harms to the user. There are also potential social harms around the impact 
that opioid dependence can have on those other than the user.  
Recommendation 3 
The ACMD recommends that prescribers and other healthcare 
professionals who prescribe, or come into contact with people who use 
tramadol should be given appropriate training and support concerning 
its misuse and adverse effects, especially with regards to its „dual-
action‟.  
This training, together with classification (see recommendation 1), will 
support prescribers and healthcare professionals in reducing harm 
associated with the misuse or inappropriate prescribing of tramadol. 
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